Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 283

1.

Influence of renal and hepatic impairment on the pharmacokinetic and pharmacodynamic properties and tolerability of fluticasone furoate and vilanterol in combination.

Allen A, Davis A, Hardes K, Tombs L, Kempsford R.

Clin Ther. 2012 Dec;34(12):2316-32. doi: 10.1016/j.clinthera.2012.11.001. Epub 2012 Nov 30.

PMID:
23200625
2.

Pharmacodynamics and pharmacokinetics of fluticasone furoate/vilanterol in healthy Chinese subjects.

Chen X, Zheng X, Jiang J, Hu P, Wu K, Zhuang L, Liu L, Du X, Kempsford R, Allen A.

Pharmacotherapy. 2015 Jun;35(6):586-99. doi: 10.1002/phar.1598. Epub 2015 Jun 9.

3.

Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.

Boscia JA, Pudi KK, Zvarich MT, Sanford L, Siederer SK, Crim C.

Clin Ther. 2012 Aug;34(8):1655-66.e5. doi: 10.1016/j.clinthera.2012.06.005. Epub 2012 Jul 11.

PMID:
22789766
4.

The safety, pharmacokinetics and pharmacodynamics of a combination of fluticasone furoate and vilanterol in healthy Japanese subjects.

Nakahara N, Wakamatsu A, Kempsford R, Allen A, Yamada M, Nohda S, Hirama T.

Int J Clin Pharmacol Ther. 2013 Aug;51(8):660-71. doi: 10.5414/CP201822.

PMID:
23735179
5.
6.

A repeat-dose thorough QT study of inhaled fluticasone furoate/vilanterol combination in healthy subjects.

Kempsford R, Allen A, Kelly K, Saggu P, Crim C.

Br J Clin Pharmacol. 2014 Mar;77(3):466-79. doi: 10.1111/bcp.12243.

7.

The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of inhaled fluticasone furoate and vilanterol trifenatate in healthy subjects.

Kempsford R, Allen A, Bal J, Rubin D, Tombs L.

Br J Clin Pharmacol. 2013 Jun;75(6):1478-87. doi: 10.1111/bcp.12019.

8.

Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trial.

Martinez FJ, Boscia J, Feldman G, Scott-Wilson C, Kilbride S, Fabbri L, Crim C, Calverley PM.

Respir Med. 2013 Apr;107(4):550-9. doi: 10.1016/j.rmed.2012.12.016. Epub 2013 Jan 16. Erratum in: Respir Med. 2013 Dec;107(12):2092-3.

9.

A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD.

Agustí A, de Teresa L, De Backer W, Zvarich MT, Locantore N, Barnes N, Bourbeau J, Crim C.

Eur Respir J. 2014 Mar;43(3):763-72. doi: 10.1183/09031936.00054213. Epub 2013 Oct 10.

10.

Inhaled fluticasone furoate/vilanterol does not affect hypothalamic-pituitary-adrenal axis function in adolescent and adult asthma: randomised, double-blind, placebo-controlled study.

Allen A, Schenkenberger I, Trivedi R, Cole J, Hicks W, Gul N, Jacques L.

Clin Respir J. 2013 Oct;7(4):397-406. doi: 10.1111/crj.12026. Epub 2013 Jun 5.

11.

Tolerability of fluticasone furoate/vilanterol combination therapy in children aged 5 to 11 years with persistent asthma.

Oliver A, VanBuren S, Allen A, Hamilton M, Tombs L, Inamdar A, Kempsford R.

Clin Ther. 2014 Jun 1;36(6):928-939.e1. doi: 10.1016/j.clinthera.2014.03.014. Epub 2014 Apr 30.

12.

Effects of hepatic impairment on the pharmacokinetics of nilotinib: an open-label, single-dose, parallel-group study.

Yin OQ, Gallagher N, Tanaka C, Fisher D, Sethuraman V, Zhou W, Lin TH, Heuman D, Schran H.

Clin Ther. 2009;31 Pt 2:2459-69. doi: 10.1016/j.clinthera.2009.11.015.

PMID:
20110053
13.

Population pharmacokinetics of inhaled fluticasone furoate and vilanterol in adult and adolescent patients with asthma.

Allen A, Siederer S, Yang S.

Int J Clin Pharmacol Ther. 2016 Apr;54(4):269-81. doi: 10.5414/CP202438.

PMID:
26902504
14.

Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the β2 agonist vilanterol administered once daily for 52 weeks in patients >=12 years old with asthma: a randomised trial.

Busse WW, O'Byrne PM, Bleecker ER, Lötvall J, Woodcock A, Andersen L, Hicks W, Crawford J, Jacques L, Apoux L, Bateman ED.

Thorax. 2013 Jun;68(6):513-20. doi: 10.1136/thoraxjnl-2012-202606. Epub 2013 Feb 25.

15.

Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials.

Dransfield MT, Bourbeau J, Jones PW, Hanania NA, Mahler DA, Vestbo J, Wachtel A, Martinez FJ, Barnhart F, Sanford L, Lettis S, Crim C, Calverley PM.

Lancet Respir Med. 2013 May;1(3):210-23. doi: 10.1016/S2213-2600(13)70040-7. Epub 2013 Apr 12. Erratum in: Lancet Respir Med. 2013 May;1(3):186.

PMID:
24429127
16.

Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients.

Dransfield MT, Feldman G, Korenblat P, LaForce CF, Locantore N, Pistolesi M, Watkins ML, Crim C, Martinez FJ.

Respir Med. 2014 Aug;108(8):1171-9. doi: 10.1016/j.rmed.2014.05.008. Epub 2014 Jun 19.

17.

Pharmacokinetics of fluticasone furoate, umeclidinium, and vilanterol as a triple therapy in healthy volunteers.

Brealey N, Gupta A, Renaux J, Mehta R, Allen A, Henderson A.

Int J Clin Pharmacol Ther. 2015 Sep;53(9):753-64. doi: 10.5414/CP202390. Erratum in: Int J Clin Pharmacol Ther. 2016 Jan;54(1):76-80.

18.

A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD.

Kerwin EM, Scott-Wilson C, Sanford L, Rennard S, Agusti A, Barnes N, Crim C.

Respir Med. 2013 Apr;107(4):560-9. doi: 10.1016/j.rmed.2012.12.014. Epub 2013 Jan 23. Erratum in: Respir Med. 2013 Dec;107(12):2094.

19.
20.

Pharmacodynamic and pharmacokinetic assessment of fluticasone furoate + vilanterol for the treatment of asthma.

Calzetta L, Rinaldi B, Cazzola M, Matera MG.

Expert Opin Drug Metab Toxicol. 2016 Jul;12(7):813-22. doi: 10.1080/17425255.2016.1192125. Epub 2016 Jun 9. Review.

PMID:
27253498

Supplemental Content

Support Center